Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3680 in metastatic castration-resistant prostate cancer (Phase I/II)
CTR20160047Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa), sponsored by Hengrui Therapeutics. Started Feb 2016; status: completed.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20160047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160047.